Result of General Meeting
23 Jan 2020
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
REDX PHARMA PLC
(“Redx” or “the Company”)
Result of General Meeting
Alderley Park, 21 January 2020 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that at the General Meeting of the Company held earlier today, all resolutions put to the meeting were duly passed.
As a consequence of the capitalisation of the loan agreement (the “Loan”) with Moulton Goodies Limited (“MGL”) as announced on 31 December 2019, 52,030,789 new ordinary shares will be issued and allotted to MGL on 22 January 2020. At such point the Loan will have been discharged in full and cease to be a debt of the Company meaning there will be no requirement on the Company to repay the Loan or any other amount to MGL.
Following admission on 22 January 2020 of the 52,030,789 new ordinary shares and in accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, it will have 178,508,703 ordinary shares of 1p each in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in Redx will be 178,508,703. The International Identification Number (“ISIN”) for Redx’s ordinary shares is GB00BSNB6S51.
The table below sets out the details of the votes put to shareholders, with resolution 3 being duly passed on a poll:
|Resolution number||Resolution name||Number of votes for & discretionary||% of votes for & discretionary||Number of votes against||% of votes against||% votes withheld||Total votes cast (including withheld)|
|3||Rule 9 waiver||43,824,136||99.99%||4,486||0.01%||0.01%||43,833,624|
For further information, please contact:
|Redx Pharma Plc||T: +44 1625 469 920|
|Lisa Anson, Chief Executive Officer|
|James Mead, Chief Financial Officer|
|Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)||T: +44 20 7894 7000|
|WG Partners LLP (Joint Broker and Financial Adviser)||T: +44 20 3705 9330|
|Claes Spång/Chris Lee/David Wilson|
|FTI Consulting||T: +44 20 3727 1000|
|Simon Conway/Ciara Martin|
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/